January 2025
Qianben has received a 5-year NCI R01 grant titled “Targeting Undruggable Transcription Factor HoxB13 to Inhibit Prostate Cancer Metastasis” totaling 3.06 millions. This is the third R01 that we have obtained during the past one and a half year. Congratulations, Wang team! Reported by Duke Pathology News: “Dr. Qianben Wang Receives NCI R01 Grant Supporting Research to Inhibit Lethal Prostate Cancer Metastasis.”
December 2024
Qianben was invited by the Department of Cell & Cancer Biology, The University of Toledo to deliver a talk on December 12 in Toledo, OH. The talk was entitled “mRNA 3’UTR-targetedd therapy overcomes cancer immune evasion by restoring MHC-1 expression”.
News of Qianben’s awarded Distinguished Professorship was featured by The Pathology Report (2024 Duke Pathology Annual Magazine).
Qianben was the invited speaker for the Experimental Radiation Oncology Seminar Series held on December 5 at MD Anderson Cancer Center, Houston, TX. The talk was titled “mRNA 3’UTR-targetedd therapy overcomes cancer immune evasion by restoring MHC-1 expression”.
November 2024
Furong’s paper entitled “Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer” was accepted by Oncogene.
Visiting scholar, Dr. Yue Zhao, joined our lab. Welcome aboard, Yue!
Qianben attended SBUR 2024 Annual Meeting as the member of the Organization Committee on November 14-17, 2024, Scottsdale, Arizona.
We have successfully filed a PCT application directed to the SCORT technology on November 8, 2024.
The Serican Journal of Medicine (https://journals.ku.edu/sjm/about) launched on November 2, 2024, as a global platform for sharing advancements across medical sciences, from basic to clinical research. At its inaugural editorial board meeting, attended by 32 members, Dr. Benyi Li, Director of the Editorial Office, presented the journal’s aims and scope. Co-Editors-in-Chief Drs. Qianben Wang and Jindan Yu outlined the publication workflow and key milestones for the next two years. Reported by Duke Pathology News: “Dr. Qianben Wang Appointed as Co-Editor-In-Chief of New Serican Journal of Medicine“.
Furong successfully presented “mRNA 3′UTR-targeted therapy overcomes prostate cancer immune evasion by restoring MHC-I expression” at DCI Translational Forum on November 1, 2024.
September 2024
Hongyan attended the Business of Innovation seminar at North Carolina Biotechnology Center on September 25.
Qianben was invited by the Chinese Urological Association to present at the 31th Annual Meeting, September 19-22, Tianjin, China. The talk was titled “Overcoming the ‘undruggable’ transcription factor with a precise, safe, and effective CRISPR/Cas13-based nanotherapy for metastatic lethal prostate cancer in vivo”.
August 2024
Qianben was invited by the Association of Chinese Americans in Cancer Research (ACACR) to present at the 2024 Annual Meeting virtual seminar series, titled ‘Integrated CRISPR/Cas13-Based RNA Editing and Nanotechnology for Targeting Undruggable Transcription and Post-Transcriptional Vulnerabilities in Lethal Prostate Cancer.’
Zhifen presented a poster entitled ‘Targeting Undruggable Transcription Factor HOXB13 in Metastatic Prostate Cancer by CRISPR/Cas13d-Based Nanoparticle Therapy’ at the 2024 Gordon Research Conference (GRC) on Drug Carriers in Medicine and Biology, held at the University of Southern Maine, August 4-9, Portland, ME.
July 2024
Qianben was the invited speaker for the 7th Xiehe Academic Forum held on July 16 at the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College. The talk was titled “Integrated CRISPR/Cas13-based RNA Editing and Nanotechnology for Targeting Transcriptional and Post-Transcriptional Vulnerabilities in Lethal Cancer.”
Qianben delivered a presentation titled “Integrated CRISPR/Cas13-based RNA Editing and Nanotechnology for Targeting Transcriptional and Post-Transcriptional Vulnerabilities in Lethal Cancer” as part of the IBP Seminar series at the Institute of Biophysics, Chinese Academy of Sciences, on July 8 in Beijing, China.
Qianben gave a talk at the Peking University School of Basic Medical Sciences Dean’s Forum on July 5 in Beijing, China, entitled “Integrated CRISPR/Cas13-based RNA Editing and Nanotechnology for Targeting Transcriptional and Post-Transcriptional Vulnerabilities in Lethal Cancer”.
Qianben gave a talk at Hubei University of Chinese Medicine in Wuhan, China, on July 4, entitled “Gene Regulation and Gene Therapy: Concepts and Approaches in Research.”
June 2024
Qianben’s NCI R01 proposal, entitled “Targeting Undruggable Transcription Factor HoxB13 to Inhibit Prostate Cancer Metastasis,” received a perfect impact score of 10, placing it in the top 1 percentile. Congratulations!
Qianben gave a keynote speech, titled “Integrated CRISPR/Cas13-based RNA Editing and Nanotechnology for Targeting Undruggable Transcription and Post-Transcriptional Vulnerabilities in Lethal Prostate Cancer,” at the Serican Academy of Urology (SAU) 2nd Annual Meeting held in Banff, Canada, on June 13, 2024.
May 2024
Qianben was invited to attend 2024 Distinguished Professors Ceremony at Washington Duke Inn on May 23, 2024.
Hongyan was invited to attend Triangle Universities Startup Workshop on May 14-16, 2024 at Apella by Alexandria, Cary, NC.
Qianben was invited to attend the 2024 Duke University School of Medicine Spring Faculty Celebration at Duke Garden on May 13, 2024.
Qianben was invited to deliver a talk at Institute of Molecular Medicine, UTHealth Houston on May 3, 2024. The title of his talk was “Integrated CRISPR/Cas13-based RNA editing and nanotechnology for targeting transcription and post-transcriptional vulnerabilities in lethal prostate cancer”.
Qianben (Contact PI) and Dr. Wei Li at UC Irvine (MPI) have received a 5-year NCI R01 grant titled ‘Elucidating Alternative Polyadenylation Regulation During Prostate Cancer Progression to Castration-Resistance,’ totaling $3.29 million. Reported by Duke Pathology News: “Dr. Qianben Wang Awarded NCI R01 Grant to Research Revolutionary Approach to Prostate Cancer Treatment.” Congratulations!
April 2024
Qianben was invited to deliver a talk at University of Kentucky College of Medicine on April 15, 2024. The title of his talk was “Integrated CRISPR/Cas13-based RNA editing and nanotechnology for targeting transcription and post-transcriptional vulnerabilities in lethal prostate cancer”.
Zhifen’s abstract “Targeting undruggable transcription factor HOXB13 in metastatic prostate cancer by CRISPR/Cas13d-based nanoparticle therapy” and Furong’s abstract “Targeted engineering mRNA 3′ UTR length enhances immunotherapy response in prostate cancer” were both selected for poster presentations on AACR Annual Meeting 2024 at San Diego Convention Center on April 5-10, San Diego, CA.
March 2024
Congratulations, Qianben, on being named the BANKS ANDERSON, SR. DISTINGUISHED PROFESSOR, effective as of July 1, 2024. Distinguished Professorships represent the highest honor that Duke bestows upon its faculty members.
- Duke Today story here: https://today.duke.edu/2024/03/duke-announces-32-new-distinguished-professorships
- School of Medicine story here: https://medschool.duke.edu/news/meet-school-medicines-2024-distinguished-professors
Qianben was invited to deliver a talk at the University of California, Irvine School of Medicine, on March 6, 2024. The title of his talk was “Integrated CRISPR/Cas13-based RNA editing and nanotechnology for targeting transcription and post-transcriptional vulnerabilities in lethal prostate cancer”.
February 2024
Qianben successfully hosted the Monthly Seminar Series of Serican Academy of Urology. He invited two world-known experts in cancer translational research and drug discovery and development. Dr. Xiaole Shirley Liu delivered a talk entitled “Integrated Genomics and Computation for Cancer Target and Drug Discovery”, whereas Dr. Jiaoti Huang’s talk is “Cellular Heterogeneity of Prostate Cancer Contributes to Therapy Resistance and Disease Progression”.
January 2024
Haipei (Happy) Yao, a PhD candidate from Duke Pathology Graduate Program, has commenced her rotation in our lab. Welcome aboard, Happy!
Our 2nd Translational Research Grant titled “Inhalable Cas13d-based nanotherapy for pan-coronavirus infection: using SARS-CoV-2 Omicron as a model” (2024-2026) has been awarded funding by the North Carolina Biotechnology Center. Reported by Duke Pathology News: “Dr. Qianben Wang’s Team Moves Closer to Developing Pan-Coronavirus infection Treatment with New Research Grant.”
December 2023
Qianben gave a talk entitled “Elucidating alternative polyadenylation regulation during prostate cancer progression to castration resistance” at the 1st Serican Academy of Urology (SAU) Annual Meeting held in Cancun, Mexico.
November 2023
Qianben and Hongyan attended The 5th Annual Invented at Duke 2023 Celebration.
Qianben was invited to deliver a talk at Wayne State University/Karmanos Cancer Institute on November 15, 2023. The title of his talk was “Defining and targeting transcription factor functions in hormone-dependent cancers”.
We were invited to meet with Pfizer Ignite at NC Biotechnology Center on November 13, 2023. Hongyan presented “Cas13d-based RNA target therapy for prostate cancer metastasis” on the meeting.
Wang lab shined on the 31st Society for Basic Urologic Research (SBUR) Annual Meeting, San Antonio, TX.
- Qianben was invited to deliver a talk on November 10, 2023. The title of his talk was “Targeting undruggable transcription factors in lethal prostate cancer by CRISPR/Cas13-based nanotherapy”.
- Zhifen presented as a finalist for the EULA and Donald S. Coffey Innovative Research Award on November 9, 2023.
- Furong orally presented his work “Targeted engineering mRNA 3’UTR length enhances immunotherapy response in prostate cancer” on November 11, 2023.
Duke filed a provisional patent application (Serial number #63/547,736) for our technology “Selective cell in organ targeting (SCORT) nanoparticle system and methods of making and using same” on November 8, 2023.
October 2023
Qianben was elected as Director-At-Large of Society for Basic Urologic Research (SBUR). Reported by Duke Pathology News: ” Dr. Qianben Wang Elected as Director at Large of Society for Basic Urological Research“. Congratulations, Qianben!
Zhifen’s abstract submission entitled “Targeting undruggable transcription factor HOXB13 in metastatic prostate cancer by CRISPR/Cas13d-based nanoparticle therapy” has been accepted as a finalist for the EULA and Donald S. Coffey Innovative Research Award at the upcoming SBUR Annual Meeting . Congratulations, Zhifen!
Qianben was invited to attend the 30th Annual Prostate Cancer Foundation Scientific Retreat in Carlsbad, CA from October 26-28, 2023.
Qianben was invited to deliver a talk at Dana-Farber Cancer Institute SEMINARS IN ONCOLOGY on October 10, 2023. The title of his talk was “Defining and targeting transcription factor functions in hormone-dependent cancers”. Reported by Duke Pathology News: “Dr. Qianben Wang Presents Research on Hormone-Dependent Cancers at Harvards’s Dana-Farber Cancer Institute“.
Zhifen and Furong both received 2023 Society for Basic Urologic Research (SBUR) Trainee Travel Awards. Reported by Duke Pathology News: “Dr. Zhifen Cui and Dr. Furong Huang Receive Travel Awards for SBUR Annual Meeting“. Congratulations, Zhifen and Furong!
September 2023
Furong’s abstract “Targeted Engineering mRNA 3′UTR Length Enhances Immunotherapy Response in Prostate Cancer” was selected for oral presentation at 2023 SBUR Annual Meeting in San Antonio, TX.
Qianben was invited to deliver a talk at Beijing Institute of Genomics, Chinese Academy of Sciences/China National Center for Bioinformation on September 22, 2023. The title of his talk was “Defining and targeting transcription factor functions in hormone-dependent cancers”.
August 2023
Ziqin Wang, a PhD candidate from Duke Pathology Graduate Program, has commenced his rotation in our lab. Welcome aboard, Ziqin!
Qianben has been appointed Chair of the Abstract and Travel Award Selection Committee for the 2023 Society for Basic Urologic Research (SBUR) Annual Meeting, scheduled to take place in San Antonio, Texas this November. In addition, he has been honored with the selection as the Scientific Program Chair for the 2025 SBUR Annual Meeting. Reported by Duke Pathology News: “Dr. Qianben Wang selected as Scientific Program Chair for 2025 SBUR Annual Meeting “.
July 2023
Our invited mini review article entitled “Deciphering and Targeting Host Factors to Counteract SARS-CoV-2 and Coronavirus Infections: Insights from CRISPR Approaches” was accepted by Frontiers in Genome Editing, section Genome Editing in Human Health and Disease.
June 2023
The Wang lab’s inaugural grant for prostate cancer translational research (2023-2025) has been awarded funding by the North Carolina Biotechnology Center, representing a significant milestone in our endeavors to bridge scientific discoveries with practical applications. Reported by Duke Pathology News: “Dr. Wang’s Team Receives N.C. Biotechnology Center Grant to Develop Prostate Cancer Treatment“; also reported by Duke OTC (Office of Translation & Commercialization) and NC Biotechnology Center: “NC Biotech Awards $2.75 Million in Grants, Loans in Latest Quarter.”
Hongyan presented “Cas13d-based RNA target therapy for prostate cancer metastasis” at Duke New Ventures Biotech Workshop on June 14, 2023.
Qianben has been awarded a 5-year NCI R01 grant titled “Targeting MED31-driven transcription recycling in lethal prostate cancer,” amounting to 2.63 million dollars. This R01 grant received an exceptional impact score of 10 and was rated in the 1st percentile. Reported by Duke Pathology News: “Dr. Qianben Wang Awarded NCI R01 Grant to Research Prostate Cancer Treatment“.
December 2022
Qianben obtained a DOD Prostate Cancer Program Idea Development Award entitled “Targeting oncogenomic function of N-Myc to inhibit neuroendocrine prostate cancer visceral metastasis”. Reported by Duke Pathology News: “Dr. Wang Receives DoD Grant for Neuroendocrine Prostate Cancer Research“.
November 2022
Qianben, Furong and Zhifen attended The 30th Society for Basic Urologic Research (SBUR) Annual Meeting, November 11-13, 2022.
Furong presented his poster entitled “Suppression of prostate cancer growth by targeted engineering mRNA 3’UTR length”.
October 2022
Zhifen orally presented “Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection” at Department of Pathology Retreat on October 15, 2022 at 21C Museum Hotel, Durham, NC. Zhifen’s poster also won the 1st Prize at the Poster Contest.
Furong poster presented ” Suppression of prostate cancer growth by targeted engineering mRNA 3’UTR length” at Department Retreat on October 15,2022.
September 2022
A collaborative NIH contract entitled “Adjuvant Comparison and Characterization” was funded. We will work with Dr. Herman Staats (PI) to compare vaccine adjuvants for their ability to modulate epigenetic regulation of gene expression. Reported by Duke Pathology News: “Staats Lab Receives NIH Funding for Adjuvant Comparison Contract.”
August 2022
- Together with other award recipients , Qianben and Hongyan celebrated their 5 years of service at Duke Department of Pathology on August 9.
- More media outlets picked up our CRISPR-SARS-CoV-2 story and run the following features.
The Telegraph (UK): Taking a puff on a new inhaler can stop you getting COVID, *also carried by New Zealand Herald
Durham Reporter: Duke Med researcher on new COVID approach:’This is just to prevent the virus to enter the cell‘
WAVY NBC-10: Prepping treatments for COVID regardless of mutation (*clip begins @ 04:46:00), *also carried by WVBT FOX-43, Norfolk
July 2022
- Reported by Duke Daily, Duke Health and Duke Pathology News: “CRISPR Technology Demonstrates Success in Preventing and Treating COVID”.
Qianben Wang, PhD, led a group of researchers who published their results about a new strategy to prevent and treat COVID in Nature Chemical Biology on Tues., July 26.
“This is a major breakthrough because with the current COVID-19 vaccine, people need to develop the antibody,” Wang said. “But our strategy does not need them to develop the antibody to neutralize the virus.”
“I am working on developing the Nano inhaler to prevent and treat coronavirus infections,” Wang added. “This unique strategy should work for many types of coronaviruses, as our targeted host proteases mediate almost all types of coronavirus cell entry (e.g, SARS-CoV-1, MERS-CoV, SARS-CoV-2 and its delta and omicron variants).”
Many media outlets have already picked up the story and run the following features.
CBS17: Duke researchers say new method to prevent/treat COVID shows promise in animal studies
WGHP FOX-8: Scientists study a mutation-proof treatment for COVID-19
WTVD ABC-11(45-second video): New treatment in development at Duke shows promise against COVID-19
The News & Observer: Duke researchers edit genes to prevent, treat COVID-19 in the lab. Will it work in people?
*also carried by The Herald Sun, The Seattle Times, The Miami Herald, Phys.org, and AOL
MedicalXpress.com: CRISPR technology demonstrates success in preventing and treating COVID
News Medical Life Sciences: Using CRISPR technology to successfully prevent and treat SARS-CoV-2 infections
Duke University SOM News Room: CRISPR Technology Demonstrates Success in Preventing and Treating COVID
- Qianben was invited to deliver a talk at The Ohio State University. The title of his talk was “Identifying and targeting poorly druggable factors in hormone-dependent cancers and COVID-19”.
June 2022
Zhifen’s paper entitled “Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection” was accepted by Nature Chemical Biology.
May 2022
- Our collaborative paper with Victor Jin lab entitled “Dynamic nucleosome landscape elicits a novel noncanonical GATA2 pioneer model” was accepted by Nature Communications. Zhong shares co-first authorship and Furong is a co-author. Victor and Qianben jointly supervised this work.
- Qianben was appointed to NIH Cancer Molecular Pathobiology (CAMP) Study Section
- A collaborative NCI R01 grant was awarded. We will work with Dr. Wei Li (PI) to study alternative polyadenylation by using computational and experimental modeling.
March 2022
Zhong’s paper entitled “Phosphorylated MED1 links transcription recycling and cancer growth” was accepted by Nucleic Acids Research.
February 2022
Qianben was invited to deliver a talk at University of Kentucky Department of Toxicology & Cancer Biology Seminar Series. The title of his talk was “Epigenetic and transcriptional regulation in hormone-dependent cancers”.
December 2021
Qianben was awarded by the Mike Slive Foundation for Prostate Cancer Research’s pilot grant program.
Reported by Duke Pathology News: “Dr. Qianben Wang receives Mike Slive Foundation Award.”
November 2021
Furong’s DoD Early Investigator Research Award application was recommended for funding.
Reported by Duke Pathology News: “Postdoctoral fellow in Wang Lab receives DoD Early Investigator Award.”
Reported by DCI News: “Huang receives DoD prostate cancer research award.”
October 2021
Zhong’s paper entitled “Transcription recycling assays identify PAF1 as a driver for RNA Pol II recycling” was accepted by Nature Communications.
September 2021
Kexin Li from Peking Union Medical College joined the lab as a postdoctoral fellow. Welcome, Kexin!
June 2021
May 2021
Qianben was invited to serve on the School of Medicine Clinical Sciences Appointment, Promotion, and Tenure Committee at Duke University.
April 2021
Qianben was invited to deliver lectures (virtual) at Louisiana State University and UNC Chapel Hill. The title of his talk was “Epigenetic regulation in hormone-dependent cancers”.
March 2021
Qianben organized the 2021 NCI virtual visit to San Antonio-Duke University Research Center for Cancer Systems Biology on March 31, 2021. Center PIs presented project progress at the virtual meeting. Agenda for 2021 NCI Virtual Visit to SA-Duke U54 Center.
December 2020
September 2020
Furong’s paper entitled “The oncogenomic function of androgen receptor in esophageal squamous cell carcinoma is directed by GATA3” was accepted by Cell Research.
August 2020
Zhong was awarded a five-year NCI R50 grant entitled “Systems analysis of the prostate cancer epigenome”. Reported by Duke Pathology News: “Chen Receives National Cancer Institute R50 Research Specialist Award.”
July 2020
Furong successfully defended his dissertation and obtained his PhD degree in June. He joined the lab as a fresh postdoctoral fellow. Welcome, Furong!
June 2020
Qianben was awarded a pilot grant from Duke Cancer Institute.
May 2020
Bill’s paper entitled “Prostate cancer cell phenotypes remain stable following PDE5 inhibition in the clinically relevant range” was accepted by Translational Oncology.
February 2020
Our invited review article entitled “Shaping chromatin states in prostate cancer by pioneer transcription factors” was accepted by Cancer Research.
February 2020
Qianben obtained a DOD Prostate Cancer Program Idea Development Award entitled “Targeting neuroendocrine prostate cancer by engineering 3′ untranslated regions”.
November 2019
Qianben was invited to speak at the 2019 Society for Basic Urological Research (SBUR) annual meeting in New Orleans, LA. The title of his talk was “Epigenomic approaches to discover transcriptional vulnerabilities of prostate cancer”.
Fuwen presented a poster at the meeting entitled “Molecular determinants for enzalutamide-induced oncogenic transcription in prostate cancer”.
Bill presented a poster at the meeting entitled “Prostate cancer cell phenotypes are stable following PDE5 inhibition in the clinical range but antagonized by supraphysiological concentrations.”
Reported by Duke Pathology News: “Duke Well Represented at SBUR Meeting“.
October 2019
Fuwen’s DoD Early Investigator Research Award application was funded. Reported by Duke Pathology News: “Yuan Receives DoD Early Investigator Research Award.”
Zhifen’s DoD Early Investigator Research Award application was recommended as alternate.
October 2019
Fuwen’s review article entitled “Alternative polyadenylation of mRNA and its role in cancer” was accepted by Genes & Diseases.
September 2019
Fuwen’s paper entitled “Molecular determinants for enzalutamide- induced transcription in prostate cancer” was accepted by Nucleic Acids Research.
Jinjin Wu from Department of Pathology started rotation in our lab. Welcome, Jinjin!
August 2019
Haiyan He from Penn State University joined the lab as a postdoctoral fellow. Welcome, Haiyan!
May 2019
Qianben was invited to deliver a lecture at the Vancouver Prostate Cancer Centre in Canada. The title of his talk was “Epigenomic approaches to discover transcriptional vulnerabilities of prostate cancer”.
April 2019
In conjunction with the NCI visit to the San Antonio-Duke University Research Center for Cancer Systems Biology on April 19th, 2019, Drs. Qianben Wang, Victor Jin and Nameer Kirma co-organized a one-day San Antonio-Duke Cancer Systems Biology Symposium, “Modeling and Interrogation of Hormone-Independent Cancer Progression” at the University of Texas Health San Antonio campus. Our center PIs and postdocs including Drs. Qianben Wang and Fuwen Yuan presented project progress at the symposium. https://pathology.duke.edu/news/wang-co-organizes-san-antonio-duke-cancer-systems-biology-symposium
News on U54 website: http://molecularmedicine.uthscsa.edu/CSBC_U54.aspx
April 2019
Our San Antonio-Duke University Research Center for Cancer Systems Biology proposed session “Systems Epigenetics in Hormone-Driven Cancers” was selected by the 2019 AACR Program Committee as a Major Symposium. Center PIs Drs. Tim Huang and Qianben Wang as well as Dr. Myles Brown from Harvard presented at this Major Symposium during the 2019 AACR Annual Meeting (Atlanta, GA)
Reported by Duke Pathology News: “Duke Pathology Featured at AACR Meeting in Atalanta.”
March 2019
Lu Tang joined the lab as a visiting scholar. Welcome, Lu!
October 2018
We moved to a new lab space at Room 1014, GSRB1!!
September 2018
Zhifen Cui from Shanghai Institute of Applied Physics, Chinese Academy of Sciences joined the lab as a postdoctoral fellow. Welcome, Zhifen!
September 2018
Qianben was invited to present on The 12th National Symposium on Prostate Cancer and Dr. Sidney A. McNairy Jr. Student Symposium in Atlanta, GA.
September 2018
Qianben was invited to present on 2018 Duke Basic Science Day: “Genomic Determinants for Andorgen Receptor-V7 Oncogenic Function in Castration-Resistant Prostate Cancer.”
September 2018
Furong Huang from Peking Union Medical College joined the lab as a visiting scholar. Welcome, Furong!
August 2018
Kathryn Ware joined the lab as a senior research associate. She is co-supervised by Drs. Qianben Wang and Andrew Armstrong. Welcome, Kathryn!
June 2018
William (Bill) Hankey has been selected as one of the only two trainees in NIH T32 Post-Doctoral Program in Genomic Medicine at The Duke Center for Applied Genomics and Precision Medicine. Congratulations, Bill !!
Reported by Duke Center for Applied Genomics & Precision Medicine: ” New Postdoc fellows ready to dive into genomic research“.
Reported by Duke Pathology News: “Hankey Selected NIH T32 Post-Doc Training Program“.
June 2018
Qianben was awarded a pilot grant from Duke Cancer Institute.
May 2018
Fuwen Yuan from Peking University joined the lab as a postdoctoral fellow. Welcome, Fuwen!
May 2018
Zhong’s paper entitled “Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13” was accepted by PNAS.
Commentary by and on PNAS: “HoxB13 mediates AR-V7 activity in prostate cancer“.
Reported by Duke University School of Medicine News and Communications and Reprinted on Duke Pathology News: “Researchers Identify Promising New Drug Target for Lethal Prostate Cancer“.
Reported by DukeMed Alumni News, Fall 2018 (Page 7): “Research Points to Promising New Target in Prostate Cancer“.
April 2018
Qianben was invited to present on 2018 Duke Department of Pathology Retreat: ““Diverse AR-V7 cistromes in castration-resistant prostate cancer are govern by HoxB13”.
December 2017
Qianben Wang’s lab moved from The Ohio State University to Duke University Department of Pathology and Duke Cancer Institute.
Hongyan Wang joined the lab as a senior research scientist/lab manager. Welcome, Hongyan!
William Hankey joined the lab as a postdoctoral fellow. Welcome, Bill!
November 2017
David Frankhouser (co-supervised by Drs. Lisa Yee and Qianben Wang) earned his PhD upon successful defense of his thesis entitled “Methylome analysis: From computation workflow development to implementation in a breast cancer prevention trial”.
October 2017
Qianben was invited to speak at the NCI Cancer Systems Biology Consortium Annual Meeting (Boston, Massachusetts).
August 2017
Qianben served as a co-chair of the “Nuclear Receptor Function and Co-factors” session of the Gordon Research Conference on Hormone-Dependent Cancers (Newry, Maine).
July 2017
Drs. Qianben Wang, Jiaoti Huang, and Steven Clinton were awarded a Multi-PI NCI R01 grant entitled “Role of oncogenic phosphorylated MED1 in aggressive prostate cancer”.
June 2017
Qianben obtained a NIGMS R01 grant entitled “Novel genomic mechanism for ligand-dependent transcription by androgen receptor”.
May 2017
Drs. Tim Huang, Victor Jin and Qianben Wang were awarded a five-year Multi-PI NCI U54 center grant totaling $9.12 million entitled “Systems Analysis of Epigenomic Architecture in Cancer Progression”. Our center is one of only nine NCI funded Cancer Systems Biology Centers in the country (https://www.cancer.gov/about-nci/organization/dcb/research-programs/csbc/announcement; https://csbconsortium.org/?page_id=476).
Qianben serves as a PI to provide oversight for Project 2 tasks and outreach and administrative activities. Qianben is also Experimental Leader of Project 2.
August 2016
Drs. Qianben Wang, Jiaoti Huang, and Steven Clinton have been awarded a Multi-PI Synergistic Idea Award by the Department of Defense Prostate Cancer Research Program. The project is entitled “Novel Tumor Suppressive Role of Phosphodiesterases in Prostate Cancer”.
March 2016
Ben earned his PhD in Biochemistry upon successful defense of his dissertation entitled “Looking beyond the androgen receptor for transcriptional drivers of prostate cancer.”
January 2016
Ben and Dayong’s paper entitled “Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence” was accepted by Nucleic Acids Research.
August 2015
Zhong’s paper entitled “Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer” was accepted by Nature Communications.
August 2015
Kaifu and Zhong’s paper entitled “Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes.” was accepted by Nature Genetics.
June 2015
Qianben received an OSU Pelotonia Idea Grant with our Co-PI, Dr. Steven Clinton.
December 2014
Zhong’s paper entitled “Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer” was accepted by EMBO J.
July 2014
Qianben received an OSU Pelotonia Idea Grant with our Co-PI, Dr. Steven Clinton.
July 2014
Ben was awarded a Ruth L. Kirschstein National Research Service Award (NRSA, F31) from the NIH/NCI.
May 2014
Ben received an award for “Outstanding Poster Presentation” at the annual Life Sciences Interdisciplinary Graduate Programs (IGP) Symposium.
May 2014
Ben was selected for the 2014 cohort of the Pelotonia Graduate Student Fellowship program.
December 2013
Dayong and Ben’s paper entitled “Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer” was accepted by Nucleic Acids Research. The article has been selected by the editors of Nucleic Acids Research as a Breakthrough Article.
December 2013
Zhenqing and Zhong’s paper entitled “Computational analysis reveals a correlation of exon-skipping events with splicing, transcription and epigenetic factors” was accepted by Nucleic Acids Research.
September 2013
Qianben was promoted to an Associate Professor with Tenure.
July 2013
Qianben was invited to serve on the Editorial Board of Molecular Cancer Research (AACR journal).
September 2012
Xiangtao Liu from Yale University joined the Wang lab as a postdoctoral fellow. He is co-mentored by Dr. Shili Lin at the Department of Statistics. Welcome, Xiangtao!
July 2012
Cassandra has been awarded a NIH T32 Oncology Training Grant. Congratulations, Cassandra!
July 2012
Cassandra Grenade joined the Wang lab as a postdoctoral fellow. Welcome, Cassandra!
June 2012
Qianben received a 2012 Endocrine Society Early Investigators Award.
June 2012
Ben Sunkel was accepted into the Howard Hughes Medical Institute (HHMI) MED into GRAD Scholars Program at The Ohio State University. Congratulations, Ben!
June 2012
Ben Sunkel from the Ohio State Biochemistry Graduate Program (OSBP) joined the Wang lab as a graduate student. Welcome!
December 2011
Qianben’s proposal was recommended for funding by Department of Defense Prostate Cancer Research Program (Idea Development Award – Established Investigators).
November 2011
Chunpeng published an article entitled “Definition of a FoxA1 Cistrome That Is Crucial for G1 to S-Phase Cell-Cycle Transit in Castration-Resistant Prostate Cancer” in Cancer Research.
October 2011
Qianben was awarded the 2011 V Scholar grant
Qianben obtained his OSU pelotonia idea grant
September 2011
Ying Ying Lee from Chinese University of Hong Kong joined us as a Visiting Scholar. Welcome!
August 2011
Our invited review article entitled “Androgen receptor-driven chromatin looping in prostate cancer” was published in Trends Endocrinol Metab.
Qianben obtained a NCI R01 grant.
July 2011
Hongyan published an article entitled “CCI-779 Inhibits Cell-Cycle G2/M Progression and Invasion of Castration-Resistant Prostate Cancer via Attenuation of UBE2C Transcription and mRNA Stability” in Cancer Research.
June 2011
Zhong published an article entitled “Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth” in EMBO J.
November 2010
Qianben received a “2010 Young Investigator Award” from Society for Basic Urologic Research
August 2010
Zhong published a review article entitled “Histone modifications and chromatin organization in prostate cancer” in Epigenomics.
February 2010
The Ohio State-Indiana University Center for Cancer Systems Biology, lead by Dr. Tim Huang, was funded by the National Cancer Institute. Dr. Wang becomes the prostate cancer project leader.
July 2009
Our paper entitled “Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer” was published by Cell as the Featured Article.
